All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

ASH 2018 | Practice changing abstracts in graft-versus-host disease 

Did you miss ASH 2018? The GvHD Hub attended the 60th ASH Annual Meeting & Exposition, December 1–4 2018, San Diego, CA, USA, and has developed a downloadable resource, which provides information on the practice changing abstracts across graft-versus-host disease (GvHD).

Our selection of ASH abstracts include comments from The GvHD Hub Steering Committee members on promising new therapeutic and prophylactic options; ruxolitinib for steroid refractory GvHD, KD025 for chronic GvHD, and vedolizumab for GvHD prophylaxis. Hear from the experts on the role of the microbiome, genetic risk factors and potential biomarkers in GvHD.

ASH 2018 | Practice changing abstracts in graft-versus-host disease

If you would like to view the ASH 2018 highlights, practice changing abstracts and expert opinions please find the GvHD Hub resource below:

Download Here

#601: Results from REACH1, a single-arm phase II study of ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory acute graft-vs-host disease

http://www.gvhdhub.com/medical-information/ash-2018-ruxolitinib-plus-corticosteroids-in-patients-with-steroid-refractory-acute-graft-versus-host-disease-the-reach1-trial

#602: KD025-208: A phase IIa study of KD025 for patients with chronic graft versus host disease (cGVHD) - pharmacodynamics and updated results

http://www.gvhdhub.com/medical-information/ash-2018-pharmacodynamics-and-updated-data-from-the-phase-iia-kd025-208-trial

#605: A phase Ib study of intravenous vedolizumab plus standard of care for graft-versus-host disease prophylaxis in subjects undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies: 6-month results

http://www.gvhdhub.com/medical-information/ash-2018-vedolizumab-plus-standard-of-care-to-prevent-graft-versus-host-disease-a-phase-ib-study

#603: Children and adults with steroid-refractory acute graft-versus-host disease respond to treatment with the mesenchymal stromal cell preparation "MSC-Ffm": treatment results for 92 consecutive patients

http://www.gvhdhub.com/medical-information/ash-2018-msc-ffm-for-the-treatment-of-pediatric-and-adult-patients-with-steroid-refractory-graft-versus-host-disease

#69: Metabolomics profiling after allogeneic hematopoietic stem cell transplantation unravels a specific signature in human acute GvHD

http://www.gvhdhub.com/medical-information/ash-2018-the-role-of-metabolomics-profiling-in-acute-graft-versus-host-disease

#359: Pre-transplant and peri-d100 gastrointestinal dysbiosis is associated with the subsequent development of chronic graft-versus-host disease

http://www.gvhdhub.com/medical-information/kate-a-markey-ash-2018-pre-transplant-and-peri-d100-gastrointestinal-dysbiosis-in-chronic-gvhd

#357: Genetic risk of severe chronic graft-versus-host disease defined by host-derived CXCR3 ligands

https://gvhdhub.com/medical-information/prediction-of-severe-chronic-graft-versus-host-disease-by-host-derived-cxcr3-ligand-genes

#356: Serial biomarker monitoring early after HCT identifies different risks for relapse and graft-vs-host disease

https://gvhdhub.com/medical-information/james-ferrara-ash-2018-how-biology-drives-acute-gvhd-biomarkers

Share:
More about...